Justin Hasenkamp

Summary

Country: Germany

Publications

  1. ncbi Resistance against natural killer cell cytotoxicity: analysis of mechanisms
    J Hasenkamp
    Department of Haematology and Oncology, Georg August University of Goettingen, Goettingen, Germany
    Scand J Immunol 64:444-9. 2006
  2. ncbi Self-tolerance of human natural killer cells lacking self-HLA-specific inhibitory receptors
    J Hasenkamp
    Department of Haematology and Oncology, Georg August University of Goettingen, Goettingen, Germany
    Scand J Immunol 67:218-29. 2008
  3. ncbi Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cells
    Justin Hasenkamp
    Department of Haematology and Oncology, Georg August University Goettingen, Robert Koch Str 40, 37099 Goettingen, Germany
    Ann Hematol 89:341-8. 2010
  4. ncbi B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression
    Andrea Borgerding
    Department of Haematology and Oncology, Georg August University of Gottingen, Gottingen, Germany
    Exp Hematol 38:213-21. 2010
  5. ncbi Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue
    Karin Hohloch
    Department of Hematology and Oncology, University Medicine, Georg August University, Robert Koch Str 40, 37075 Gottingen, Germany
    Ann Hematol 90:1307-15. 2011
  6. ncbi Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect
    B Glass
    Universtitätsklinikum Göttingen, Robert Koch Strasse 40, Gottingen, Germany
    Bone Marrow Transplant 34:391-7. 2004
  7. ncbi Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors
    Roland Schroers
    Department of Hematology and Oncology, Georg August Universitaet Goettingen, Goettingen, Germany
    Exp Hematol 32:536-46. 2004
  8. ncbi Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
    Andrea Borgerding
    Department of Hematology and Oncology, Georg August University Goettingen, 37075 Goettingen, Germany
    Ann Hematol 89:283-9. 2010
  9. ncbi Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma
    G G Wulf
    Bone Marrow Transplant 36:271-3. 2005

Detail Information

Publications9

  1. ncbi Resistance against natural killer cell cytotoxicity: analysis of mechanisms
    J Hasenkamp
    Department of Haematology and Oncology, Georg August University of Goettingen, Goettingen, Germany
    Scand J Immunol 64:444-9. 2006
    ..In conclusion, revealing the mechanisms of resistance against NK cell-mediated cytotoxicity may allow improving the results of NK-based immunotherapy...
  2. ncbi Self-tolerance of human natural killer cells lacking self-HLA-specific inhibitory receptors
    J Hasenkamp
    Department of Haematology and Oncology, Georg August University of Goettingen, Goettingen, Germany
    Scand J Immunol 67:218-29. 2008
    ..Our results suggest alternative mechanisms than HLA-specific inhibitory receptors to control NK cell activity. But HLA seems to be involved in shaping effector function of the NK cell repertoire...
  3. ncbi Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cells
    Justin Hasenkamp
    Department of Haematology and Oncology, Georg August University Goettingen, Robert Koch Str 40, 37099 Goettingen, Germany
    Ann Hematol 89:341-8. 2010
    ..In addition, we found no relevant TiA by lymphoma cell lines against activated murine NK cells. We conclude that TiA represents only a minor factor of target cell resistance against NK cell-mediated cytolysis...
  4. ncbi B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression
    Andrea Borgerding
    Department of Haematology and Oncology, Georg August University of Gottingen, Gottingen, Germany
    Exp Hematol 38:213-21. 2010
    ..Resistance to this treatment occurs, although CD20 antigen is expressed on the tumor cells...
  5. ncbi Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue
    Karin Hohloch
    Department of Hematology and Oncology, University Medicine, Georg August University, Robert Koch Str 40, 37075 Gottingen, Germany
    Ann Hematol 90:1307-15. 2011
    ..Tandem transplants consisting of HD chemotherapy followed by HD-RIT with (131)I-coupled anti-CD20 are manageable and effective but toxic treatment modalities for relapsed poor prognosis CD20+ B-NHL...
  6. ncbi Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect
    B Glass
    Universtitätsklinikum Göttingen, Robert Koch Strasse 40, Gottingen, Germany
    Bone Marrow Transplant 34:391-7. 2004
    ..These results support the existence of a clinically relevant GVL effect in aggressive lymphoma. T-cell depletion (or CD34 selection) of grafts is not recommended in patients with poor-risk aggressive NHL...
  7. ncbi Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors
    Roland Schroers
    Department of Hematology and Oncology, Georg August Universitaet Goettingen, Goettingen, Germany
    Exp Hematol 32:536-46. 2004
    ..In this study, we examined the gene transfer into T lymphocytes and NK cells using Ad5/F35 compared with conventional Ad5 adenovectors...
  8. ncbi Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
    Andrea Borgerding
    Department of Hematology and Oncology, Georg August University Goettingen, 37075 Goettingen, Germany
    Ann Hematol 89:283-9. 2010
    ..Lasting remissions were achieved only by high-dose chemotherapy with stem cell transplantation...
  9. ncbi Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma
    G G Wulf
    Bone Marrow Transplant 36:271-3. 2005